Articles about the use of alimta by itself and combined with other drugs to fight mesothelioma, including cisplatin, pemetrexed, gemcitabine, and more. Studies cover phase I, II, and III trials  

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. University of Chicago, Cancer Research Center, 5841 South Maryland Ave, Chicago, IL 60637, USA. nvogelza@medicine.bsd.uchicago.edu.

Multimodality therapy in mesothelioma: role of chemotherapy.
Vogelzang NJ. Nevada Cancer Institute, 10,000 West Charleston Boulevard, Suite 260, Las Vegas, NV 89135, USA. nvogelza@nvcancer.org

Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
Taylor P, Castagneto B, Dark G, Marangolo M, Scagliotti GV, van Klaveren RJ, Labianca R, Serke M, Schuette W, van Meerbeeck JP, Heigener D, Liu Y, Adachi S, Blatter J, von Pawel J. University Hospital of South Manchester, Manchester, United Kingdom. Paul.Taylor@smuht.nwest.nhs.uk

Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C. Istituto Clinico Humanitas, Rozzano, Italy. armando.santoro@humanitas.it

Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.
Jänne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, Monberg M, Obasaju C, Kindler H. Dana Farber Cancer Institute, Lowe Center for Thoracic Oncology, 44 Binney St, Dana D820A, Boston, MA 02115, USA. pjanne@partners.org

A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies.
Rowinsky EK, Beeram M, Hammond LA, Schwartz G, De Bono J, Forouzesh B, Chu Q, Latz JE, Hong S, John W, Nguyen B. Institute for Drug Development, Cancer Therapy, and Research Center, San Antonio, Texas, USA. erowinsky@oncodrugs.com

Dramatic tumour response to pemetrexed single-agent in an elderly patient with malignant peritoneal mesothelioma: a case report.
Fasola G, Puglisi F, Follador A, Aita M, Di Terlizzi S, Belvedere O. Dept. of Medical Oncology, University Hospital, P.le S. M. Misericordia, 33100 Udine, Italy. fasola.gianpiero@aoud.sanita.fvg.it

Standard therapy for the treatment of malignant pleural mesothelioma.
Vogelzang NJ. Nevada Cancer Institute, Las Vegas, NV 89135, USA. nvogelzang@nvcancer.org

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.
Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, Nackaerts K, Lianes P, Vogelzang NJ. Heidelberg University Medical Center, Mannheim, Germany. Prof.Manegold@t-online.de

Novel combinations using pemetrexed in malignant mesothelioma.
Gadgeel SM, Pass HI. Wayne State University/Karmanos Cancer Institute, Detroit, MI 48201, USA. gadgeels@karmanos.org

Pemetrexed alone and in combination with platinum compounds in the management of malignant mesothelioma.
Suwanrusme H, Meyer ML, Green MR. Hollings Cancer Center, Medical University of South Carolina, Charleston 29425, USA.

Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C. Radiotherapy and Oncology, Medical University of Gdansk, Debinki 7 St, Gdansk, Poland. jjassem@amg.gda.pl